Welcome to our dedicated page for INNMF news (Ticker: INNMF), a resource for investors and traders seeking the latest updates and insights on INNMF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INNMF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INNMF's position in the market.
Amplia Therapeutics (OTCQB:INNMF) received a Certificate of Grant from the US Patent and Trademark Office for a patent titled A salt and crystal form of a FAK inhibitor, extending protection for the company's clinically developed FAK inhibitor narmafotinib to at least 2040 in the US and other jurisdictions. The grant follows a September 2025 notification of allowance and complements existing patents already granted in Europe, Japan, India, Korea and Australia. The patent specifically protects the particular salt/crystal form of narmafotinib being developed clinically. The company stated protection in additional regions is under review by respective patent offices and said the grants strengthen narmafotinib's long-term intellectual property position.
